GlassScriptPhysician profile
Stephanie Walls
NPI 1295225142
$13,890.18
in general payments reported to CMS, 2019-2025
49 companies · $3,104 in 2025
The $3,104 reported for 2025 was more than what 97% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,952 · 2022: $3,509 · 2023: $2,737 · 2024: $2,588 · 2025: $3,104.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,325 · Consulting Fee: $104.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,324.82 |
| Consulting Fee | $104.09 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $2,678.09 | 2021-2025 | Tezspire, Airsupra, Breztri |
| Genzyme Corporation | $1,543.51 | 2021-2025 | |
| Glaxosmithkline, LLC. | $1,431.63 | 2021-2025 | Trelegy Ellipta, Arexvy, Nucala |
| Optinose US, INC. | $752.26 | 2021-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $646.79 | 2021-2025 | Takhzyro, Aralast, Eohilia |
| Grifols USA, LLC | $642.64 | 2021-2025 | Xembify, Prolastin-C Liquid |
| Mylan Specialty L.P. | $570.58 | 2021-2024 | Yupelri |
| Regeneron Healthcare Solutions, INC. | $559.86 | 2021-2025 | Dupixent |
| Amgen INC. | $410.29 | 2021-2025 | Tezspire |
| Mallinckrodt Hospital Products INC. | $337.10 | 2021-2025 | Acthar |
| Incyte Corporation | $310.61 | 2022-2025 | Opzelura |
| Teva Pharmaceuticals USA, INC. | $300.49 | 2021-2023 | Airduo Digihaler |
| Ars Pharmaceuticals Operations, INC. | $277.41 | 2025 | Neffy |
| Alk-Abello, INC | $267.42 | 2021-2023 | Odactra, Ragwitek, Grastek |
| Genentech, INC. | $267.09 | 2022-2025 | Xolair |
Show all 49 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stephanie Walls listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.